Patent and Trademark Workplace offers granted U.

Biogen receives additional patent safety for MS drug TECFIDERA Biogen Idec today announced that the U.S . Patent and Trademark Workplace offers granted U.S. Patent No. The patent, that may expire in 2028, addresses the dosing program of daily administration of 480 mg of TECFIDERA. This regimen is roofed in the proposed advertising application for TECFIDERA, which is less than review by the U currently.S. Food and Medication Administration . Scangos, Ph.D., ceo of Biogen Idec. The European Patent Workplace also recently identified that Biogen Idec's program for a patent within the same dosing routine of TECFIDERA is allowable. Once granted, this patent would expire in 2028. The TECFIDERA dose routine patents enhance the developing portfolio of granted patents covering TECFIDERA..

Biogen Idec initiates enrollment in Stage II BG-12 mixture trial for relapsing-remitting multiple sclerosis Biogen Idec today announced enrollment of the initial individual in a multicenter Stage II clinical trial made to evaluate it is investigational oral therapy BG-12 in conjunction with commonly used first-series treatments in individuals with relapsing-remitting multiple sclerosis . Efficacy endpoints may also be assessed in a subset of patients. This pipeline contains late-stage applications such as for example BG-12, PEGylated interferon beta 1a, and daclizumab, earlier-stage applications such as anti-LINGO, and many preclinical programs.D., Ph.D., Senior Vice President of Neurology Study and Advancement at Biogen Idec.

Other Posts From Category "pharmacy news":

Related Posts